Impact of antiresorptive agents on mortality risk in postmenopausal women with osteoporosis: insights from a nationwide cohort study
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.43 95% CI 0.34–0.54Authors' conclusion
The use of ARs in postmenopausal women with osteoporosis is associated with significantly lower risks of all-cause mortality, especially from cardiovascular events and fractures. The mortality reduction benefits appear to be enhanced with prolonged AR therapy, highlighting the potential importance of sustained treatment in this population.
Study context
- Population
- Postmenopausal women with osteoporosis, National Screening Program for Transitional Ages (2008–2017), South Koreapropensity-score matched 1:1
- Participants
- 117,871 women
- Exposure
- Antiresorptive agents for ≥1 year vs no AR use
- AR usersn = 15,895
- Outcome
- All-cause mortality and cause-specific mortality (CVD and injury-/fracture-related deaths)
Methodological detailspropensity-score matched 1:1, multivariable Cox proportional hazard regression
- Propensity-score matched 1:1
- Multivariable Cox proportional hazard regression
Main finding
All-cause mortality
Hazard ratio
0.43
95% CI 0.34–0.54
Events by group
AR users
1.41 per 1000 person-years
102 of 15 895
Non-users
3.14 per 1000 person-years
221 events
AR usersvs Non-users
HR 0.43 (95% CI 0.34–0.54)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| CVD mortality52% reduction | 0.48 (0.34–0.69) | |
| Injury-/fracture-related mortality54% reduction | 0.46 (0.27–0.76) | |
| 0.20.5125Hazard ratio (log scale) |
Duration of AR use
- Consistent decrease in all-cause and cardiovascular disease (CVD) mortality risks with longer durations of AR use
Original publication
Impact of antiresorptive agents on mortality risk in postmenopausal women with osteoporosis: insights from a nationwide cohort study. Eur J Endocrinol. Published 17 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →